• No results found

High-throughput profiling of drug interactions in Gram-positive bacteria

N/A
N/A
Protected

Academic year: 2021

Share "High-throughput profiling of drug interactions in Gram-positive bacteria"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

High-throughput profiling of drug interactions in Gram-positive bacteria Cacace, Elisabetta

DOI:

10.33612/diss.167295112

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Cacace, E. (2021). High-throughput profiling of drug interactions in Gram-positive bacteria. University of Groningen. https://doi.org/10.33612/diss.167295112

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

1. Drug combinations represent a powerful resource to fight the antimicrobial resistance crisis (Chapter 1, this thesis)

2. Combinatorial complexity limits drug interaction screening attempts. Automated platforms and high-throughput data analysis greatly improve feasibility and efficiency of combinatorial screens (Chapter 2, this thesis)

3. Drug combinations can be used as multiple perturbations of

cellular processes, analogously to genetic perturbations. Accordingly, drug interactions and genetic interactions exhibit common features (Chapters 3-4, this thesis)

4. Drug interactions are known to be species-specific since the dawn of the antibiotic era. Drug interaction conservation between two species can be linked to their genomic relatedness and to their different permeability to individual drugs (Chapter 4, this thesis) 5. Even when they have no effect on bacterial growth, non-antibiotic drugs can synergize with antibiotics (or with other non-antibiotic drugs) and provide new therapeutic options against multi-drug resistant bacteria (Chapter 5, this thesis)

6. In the age of polypharmacy, non-antibiotic and antibiotic drugs are commonly co-administered. Non-antibiotic drugs can antagonize antibiotics, potentially hindering their action in real-life infection contexts

(Chapter 5, this thesis)

7. Drug-drug and drug-gene interaction data can be combined to decipher the genetic background of drug interactions, predict novel drug-drug interactions and unveil the function of uncharacterized genes (Chapter 6, this thesis)

8. “General questions never lead to more than limited answers. On

the contrary, limited questions have often led to more and more general answers” (François Jacob, “La souris, la mouche et l’homme”)

Referenties

GERELATEERDE DOCUMENTEN

This thesis was conducted within the Groningen University Institute for Drug Exploration (GUIDE). Printing of this thesis was financially supported by Faculty of Science and

enzymes metabolize about 40% of drugs used in daily clinical practice, the interaction between drug and variant CYP2C9, CYP2C19, and CYP2D6 alleles (drug-gene interaction/DGI)

Outcome measures were defined as frequency of potential CYP2D6/2C19/2C9 mediated DDIs as well as the levels of agreement between information from the self-reported Lifelines

Based on the two main knowledge-bases of DDI alert systems (G-Standaard and Pharmabase), incidences were divided between signalled (metoprolol-fluoxetine/paroxetine)

We found that the risk of discontinuation and dose adjustment of metoprolol in the metoprolol-paroxetine/ fluoxetine combination is not significantly different from

Experimental studies reported that paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of

Omeprazole and lansoprazole produced a greater magnitude of interactions with fluvoxamine than rabeprazole for all genotypes, because rabeprazole only involves CYP2C19 in

No participants with CYP2C19 UM and CYP3A4 NM/IM combination experienced drug switching and/or dose reduction and no significant association with early discontinuation as well as